Literature DB >> 12960100

Parallel phosphatidylinositol-3 kinase and p42/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells.

Andrew Grey1, Qi Chen, Xin Xu, Karen Callon, Jill Cornish.   

Abstract

IGF-I is an endocrine and paracrine regulator of skeletal homeostasis, principally by virtue of its anabolic effects on osteoblastic cells. In the current study, we examined the intracellular signaling pathways by which IGF-I promotes proliferation and survival in SaOS-2 human osteoblastic cells. Inhibition of each of the phosphatidylinositol-3 kinase (PI-3 kinase), p42/44 MAPK, and p70s6 kinase pathways partially inhibited the ability of IGF-I to stimulate osteoblast proliferation and survival. Because activation of p70s6 kinase is downstream of both PI-3 kinase and p42/44 MAPK activation in osteoblasts treated with IGF-I, this ribosomal kinase represents a convergence point for IGF-I-induced PI-3 kinase and p42/44 MAPK signaling in osteoblastic cells. In addition, abrogation of PI-3 kinase-dependent Akt signaling, which does not inhibit IGF-I-induced p70s6 kinase phosphorylation, also inhibited the antiapoptotic effects of IGF-I in osteoblasts. Finally, interruption of G beta gamma signaling partially abrogated the ability of IGF-I to promote osteoblast survival, without inhibiting signaling through PI-3 kinase/Akt, p42/44 MAPKs, or p70s6 kinase. These data suggest that IGF-I signals osteoblast mitogenesis and survival through parallel, partly overlapping intracellular pathways involving PI-3 kinase, p42/44 MAPKs, and G beta gamma subunits.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12960100     DOI: 10.1210/en.2003-0350

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  36 in total

Review 1.  Update in new anabolic therapies for osteoporosis.

Authors:  Ernesto Canalis
Journal:  J Clin Endocrinol Metab       Date:  2010-04       Impact factor: 5.958

2.  Proliferative and mineralogenic effects of insulin, IGF-1, and vanadate in fish osteoblast-like cells.

Authors:  Daniel M Tiago; M Leonor Cancela; Vincent Laizé
Journal:  J Bone Miner Metab       Date:  2010-12-23       Impact factor: 2.626

3.  Continuous subcutaneous IGF-1 therapy via insulin pump in a patient with Donohue syndrome.

Authors:  David R Weber; Diana E Stanescu; Robert Semple; Cheryl Holland; Sheela N Magge
Journal:  J Pediatr Endocrinol Metab       Date:  2014-11       Impact factor: 1.634

Review 4.  New insights into mineralogenic effects of vanadate.

Authors:  Vincent Laizé; Daniel M Tiago; Manuel Aureliano; M Leonor Cancela
Journal:  Cell Mol Life Sci       Date:  2009-09-04       Impact factor: 9.261

5.  Correlation between serum IGF-1 and blood lead level in short stature children and adolescent with growth hormone deficiency.

Authors:  Yan Xu; Ming-Chao Liu; Pei Wang; Bei Xu; Xin-Qin Liu; Zhi-Ping Zhang; Li-Fen Ren; Qing Qin; Yue-Yun Ma; Wen-Jing Luo; Xiao-Ke Hao
Journal:  Int J Clin Exp Med       Date:  2014-04-15

6.  The reciprocal regulation of gamma-synuclein and IGF-I receptor expression creates a circuit that modulates IGF-I signaling.

Authors:  Minjing Li; Yancun Yin; Hui Hua; Xiangming Sun; Ting Luo; Jiao Wang; Yangfu Jiang
Journal:  J Biol Chem       Date:  2010-07-29       Impact factor: 5.157

7.  IGF-I regulates tight-junction protein claudin-1 during differentiation of osteoblast-like MC3T3-E1 cells via a MAP-kinase pathway.

Authors:  Naoko Hatakeyama; Takashi Kojima; Kousuke Iba; Masaki Murata; Mia M Thi; David C Spray; Makoto Osanai; Hideki Chiba; Sumio Ishiai; Toshihiko Yamashita; Norimasa Sawada
Journal:  Cell Tissue Res       Date:  2008-10-15       Impact factor: 5.249

8.  The small GTPase RhoA is crucial for MC3T3-E1 osteoblastic cell survival.

Authors:  Tomohiko Yoshida; Mary F Clark; Paula H Stern
Journal:  J Cell Biochem       Date:  2009-04-01       Impact factor: 4.429

9.  Anti-insulin growth factor receptor therapy in Ewing sarcoma.

Authors:  Michael S Isakoff; Neyssa Marina
Journal:  F1000 Med Rep       Date:  2009-08-17

Review 10.  MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.

Authors:  Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2017-11-07       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.